Ketamine treatment, also known as ketamine therapy, involves the use of ketamine to alleviate symptoms of conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). It is typically administered intravenously or via an intramuscular injection.
The use of ketamine in mental health treatment is still a relatively new area of research but early studies have shown promising results. One of the benefits of ketamine treatment is that it can work quickly, often bringing about a noticeable improvement in symptoms within hours or days of treatment.
Ketamine can be delivered in various ways, and their effectiveness can vary. Oral preparations are generally less effective as they need to be metabolized by the digestive system. Sublingual administration (under the tongue) is also less effective but still very useful for specific patients. The effectiveness of intramuscular administration is comparable to IV infusion.
To summarize, the differences between these two methods can be outlined as follows:
Starting an IV infusion typically involves only one needle stick, while intramuscular injections may require multiple injections during a treatment session.
The dosage of IV infusion can be adjusted, reduced, or stopped in response to a patient’s reaction during treatment. In contrast, intramuscular administration cannot be adjusted or reversed after injection.
Some patients report that the symptom relief provided by IV infusions lasts longer between treatments compared to intramuscular injections. As a result, patients receiving intramuscular treatment may need to receive more frequent treatments.
The onset and recovery rate of the medication is also different between the two methods. Intramuscular injection has a rapid onset, which can be uncomfortable for some patients, and a slower recovery. In contrast, IV infusion has a more gradual onset and recovery.
If any adverse side effects occur during an intramuscular injection, reassurance and sometimes other medications may be necessary to counteract them and allow the medication to run its course since the administration cannot be stopped.
Both IV infusion and intramuscular administration of ketamine require supervision by a licensed, prescribing healthcare provider who has received specific training in the use of ketamine. Monitoring a patient’s vital signs throughout the treatment is also essential for ensuring their safety.
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptors are a type of receptor in the brain that are involved in the transmission of pain signals and the regulation of mood and cognition. By blocking these receptors, ketamine may help to alleviate pain and improve mood.
In addition to its effects on NMDA receptors, ketamine also affects other brain chemicals, such as glutamate, serotonin, and dopamine. These chemicals are involved in the regulation of mood, motivation, and reward. By modulating the activity of these neurotransmitters, ketamine may help to reduce symptoms of depression, anxiety, and other mental health conditions.
Ketamine, first synthesized in 1962 by Dr. Calvin Stevens, was originally developed as an anesthetic for use in human and veterinary medicine. It was approved by the U.S. Food and Drug Administration (FDA) in 1970 as an anesthetic for use in children, adults, and the elderly and quickly gained popularity for its ability to induce anesthesia with minimal respiratory depression, making it particularly useful in emergency and battlefield situations.
During the Vietnam War, ketamine was the battlefield anesthetic used the most related to the quick onset of action, with minimal respiratory and cardiac side effects, and potent analgesic properties. It is still used in the military to this day.
In 1974, Argentina started to use ketamine as an adjunct to depression with the United States starting to study the drug more for its mental health properties in the 1990s. In 1985, The World Health Organization (WHO) placed ketamine in the WHO Model List of Essential Medicines and described it as indispensable for surgery in low-middle income countries, for disaster situations, and in conflict regions.
Over the years, ketamine’s versatile properties led to its exploration in various medical applications. Ketamine’s unique characteristics, including its dissociative properties and rapid onset of action, made it a valuable anesthetic.
In recent years, there has been a resurgence of interest in ketamine for its potential therapeutic uses. Research has explored its efficacy in treating various psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). Ketamine infusion therapy has gained popularity as a treatment for treatment-resistant depression. In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine, a nasal form of ketamine, for the treatment of depression that does not respond to traditional antidepressant medications. This marked a significant milestone in the recognition of ketamine’s therapeutic potential.
